Personalis Secures UKCA Mark for NeXT Personal Dx, Expanding MRD Testing in Great Britain
Event summary
- Personalis achieved UKCA marking for its NeXT Personal Dx test on July 14, 2026, enabling clinical use across Great Britain.
- The approval allows biopharma companies to standardize MRD detection in global trials, accelerating drug development timelines.
- Link Medical Solutions Ltd. will serve as the commercialization partner for NeXT Personal Dx in Great Britain.
The big picture
Personalis' UKCA approval strengthens its position as a global leader in precision oncology, enabling seamless integration of MRD testing across US and UK clinical trials. This regulatory milestone aligns with the broader industry trend toward standardized, ultrasensitive diagnostics that support personalized cancer treatment and accelerate drug development.
What we're watching
- Market Adoption
- How quickly oncologists in Great Britain integrate NeXT Personal Dx into clinical practice.
- Biopharma Demand
- Whether the UKCA approval drives increased adoption by global biopharma companies for multi-national trials.
- Regulatory Scaling
- The pace at which Personalis can secure similar regulatory clearances in other key international markets.
Related topics